Immunotherapy against several tumors, such as lung cancer, including NSCLC
First Claim
1. A method of eliciting an immune response in a patient who has non-small cell lung carcinoma (NSCLC), lung cancer, and/or gastric cancer, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of KIQEMQHFL (SEQ ID NO:
- 2), wherein the peptide is in a complex with an MHC molecule, and wherein the activated T cells are cytotoxic T cells produced by contacting T cells, in vitro, with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell specifically against the peptide.
1 Assignment
0 Petitions
Accused Products
Abstract
A method of treating a patient who has non-small cell lung carcinoma (NSCLC), lung cancer, gastric cancer, and/or glioblastoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has NSCLC, lung cancer, gastric cancer, and/or glioblastoma. A method of treating a patient who has NSCLC, lung cancer, gastric cancer, and/or glioblastoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the NSCLC, lung cancer, gastric cancer, and/or glioblastoma.
-
Citations
12 Claims
-
1. A method of eliciting an immune response in a patient who has non-small cell lung carcinoma (NSCLC), lung cancer, and/or gastric cancer, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of KIQEMQHFL (SEQ ID NO:
- 2), wherein the peptide is in a complex with an MHC molecule, and wherein the activated T cells are cytotoxic T cells produced by contacting T cells, in vitro, with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell specifically against the peptide.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
Specification